DOTFM
From Wikipedia, the free encyclopedia
|
DOTFM
|
|
| Systematic (IUPAC) name | |
| 1-(4-(trifluoromethyl)-2,5-dimethoxyphenyl)-2-aminopropane | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C12H16F3NO2 |
| Mol. mass | 263.255 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
DOTFM is an analogue of the phenethylamine derived hallucinogen DOB where the bromine atom has been replaced by a trifluoromethyl group. It was discovered in 1994 by a team at Purdue University.
DOTFM is the amphetamine homolog of the phenethylamine hallucinogen 2C-TFM and is around twice as potent as 2C-TFM in animal studies. It acts as a potent agonist for the 5HT2A and 5HT2C receptors. In drug-substitution experiments in rats, DOTFM fully substituted for LSD and was slightly more potent than DOI.[1] Anecdotal reports from human users suggest that DOTFM is a potent hallucinogen with an extremely long duration of action, similar to Br-DFLY.
[edit] References
- ^ Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudelsky GA, Nash JF. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. Journal of Medicinal Chemistry. 1994 Dec 9;37(25):4346-51. PMID 7996545
|
|||||

